Review
doi: 10.1016/s1535-6108(03)00113-2.
Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction
Affiliations
- PMID: 12781360
- DOI: 10.1016/s1535-6108(03)00113-2
Item in Clipboard
Review
Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction
Cancer Cell.
2003 May.
Free article
Abstract
Adoptive T cell immunotherapy is an evolving technology with the potential of providing a means to safely and effectively target tumor cells for destruction.
Similar articles
-
Potential advantages of CD1-restricted T cell immunotherapy in cancer.Mol Immunol. 2018 Nov;103:200-208. doi: 10.1016/j.molimm.2018.09.025. Epub 2018 Oct 8. Mol Immunol. 2018. PMID: 30308433 Review.
-
[Molecular targets for development of cancer immunotherapy].Nihon Rinsho. 2012 Nov;70 Suppl 8:144-8. Nihon Rinsho. 2012. PMID: 23513828 Japanese. No abstract available.
-
T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.Int Immunol. 2016 Jul;28(7):349-53. doi: 10.1093/intimm/dxw022. Epub 2016 Apr 28. Int Immunol. 2016. PMID: 27127191 Review.
-
Cancer immunotherapy: a treatment for the masses.Science. 2004 Jul 9;305(5681):200-5. doi: 10.1126/science.1100369. Science. 2004. PMID: 15247469 Review.
-
Adoptive T-cell therapy of cancer.Hematol Oncol Clin North Am. 2006 Jun;20(3):711-33. doi: 10.1016/j.hoc.2006.02.008. Hematol Oncol Clin North Am. 2006. PMID: 16762731 Review.
Cited by
-
Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction.J Immunol. 2004 Dec 15;173(12):7209-16. doi: 10.4049/jimmunol.173.12.7209. J Immunol. 2004. PMID: 15585842 Free PMC article.
-
Multiomics2Targets identifies targets from cancer cohorts profiled with transcriptomics, proteomics, and phosphoproteomics.Cell Rep Methods. 2024 Aug 19;4(8):100839. doi: 10.1016/j.crmeth.2024.100839. Epub 2024 Aug 9. Cell Rep Methods. 2024. PMID: 39127042 Free PMC article.
-
Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells.Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4518-23. doi: 10.1073/pnas.0500600102. Epub 2005 Mar 9. Proc Natl Acad Sci U S A. 2005. PMID: 15758071 Free PMC article.
-
MiR-21 is required for anti-tumor immune response in mice: an implication for its bi-directional roles.Oncogene. 2017 Jul 20;36(29):4212-4223. doi: 10.1038/onc.2017.62. Epub 2017 Mar 27. Oncogene. 2017. PMID: 28346427
-
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors.Cancer Discov. 2016 Feb;6(2):133-46. doi: 10.1158/2159-8290.CD-15-0583. Epub 2015 Oct 26. Cancer Discov. 2016. PMID: 26503962 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
